Related items

On Tuesday, 21 April, AmCham EU hosted Renate Nikolay, Deputy Director-General, Directorate-General for Communications Networks, Content and Technology, European Commission, for a discussion on the growing impact of artificial intelligence (AI) on intellectual property (IP). At a time when AI is reshaping how content is created, used and shared, the exchange explored the increasing pressure on existing IP frameworks. Moderated by Carmen Lembo (Qualcomm), Chair, Intellectual Property Committee, AmCham EU, the discussion covered questions around copyright, AI training and transparency, while also highlighting the importance of a policy framework that protects rights and supports innovation in Europe’s evolving digital economy.

The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.

On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda.